Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | RAF1 | P04049 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2951112 | 0.87 | RAB9A (0.77) | EGFRRAB9AKMT2AMEN1NPC1 | |
| SCHEMBL11646450 | 0.85 | EGFR (0.59) | EGFRRAB9AKMT2AMEN1NPC1 | |
| SCHEMBL11014875 | 0.85 | RAB9A (0.62) | EGFRRAB9AKMT2AMEN1NPC1 | |
| SCHEMBL11017752 | 0.84 | EGFR (0.69) | EGFRRAB9AKMT2AMEN1NPC1 | |
| SCHEMBL11016786 | 0.84 | EGFR (0.57) | EGFRRAB9AKMT2AMEN1NPC1 | |
| SCHEMBL11015930 | 0.82 | EGFR (0.59) | EGFRRAB9AKMT2AMEN1NPC1 | |
| SCHEMBL134635 | 0.82 | RAB9A (0.66) | EGFRRAB9AKMT2AMEN1NPC1 | |
| SCHEMBL4899524 | 0.82 | RAB9A (0.66) | EGFRRAB9AKMT2AMEN1NPC1 | |
| SCHEMBL4112548 | 0.82 | EGFR (0.66) | EGFRRAB9AKMT2AMEN1NPC1 | |
| SCHEMBL11035426 | 0.81 | EGFR (0.66) | EGFRRAB9AKMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183254-B1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2017-06-21 | — | — | EP | disclosed |
| US-8907091-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-8846927-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-09-30 | — | — | US | disclosed |
| US-8569503-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2013-10-29 | — | — | US | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MAP3K19, MAP3K9, MAP4K2 | EGFR 568/4885RAB9A 1119/4885KMT2A 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.